APA

Cheng H., Ballman K., Vassilakopoulou M., Dueck A. C., Reinholz M. M., Tenner K., Gralow J., Hudis C., Davidson N. E., Fountzilas G., McCullough A. E., Chen B., Psyrri A., Rimm D. L. & Perez E. A. (20141104). EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. : British journal of cancer.

Chicago

Cheng H, Ballman K, Vassilakopoulou M, Dueck A C, Reinholz M M, Tenner K, Gralow J, Hudis C, Davidson N E, Fountzilas G, McCullough A E, Chen B, Psyrri A, Rimm D L and Perez E A. 20141104. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. : British journal of cancer.

Harvard

Cheng H., Ballman K., Vassilakopoulou M., Dueck A. C., Reinholz M. M., Tenner K., Gralow J., Hudis C., Davidson N. E., Fountzilas G., McCullough A. E., Chen B., Psyrri A., Rimm D. L. and Perez E. A. (20141104). EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. : British journal of cancer.

MLA

Cheng H, Ballman K, Vassilakopoulou M, Dueck A C, Reinholz M M, Tenner K, Gralow J, Hudis C, Davidson N E, Fountzilas G, McCullough A E, Chen B, Psyrri A, Rimm D L and Perez E A. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. : British journal of cancer. 20141104.